{{Drugbox
| IUPAC_name = 2-methyl-3-(2-methoxy-4-nitrophenyl)-4(3H)-quinazolinone
| image = Nitromethaqualone.svg
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 340-52-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 63339
| DrugBank =  
| ChemSpiderID = 57006

<!--Chemical data-->
| C=16 | H=13 | N=3 | O=4 
| molecular_weight = 311.29
| smiles = O=C1C2=CC=CC=C2N=C(N1C3=C(OC)C=C(N(=O)=O)C=C3)C
}}

'''Nitromethaqualone'''<ref>{{ cite patent | country = US | number = 3162634 | status = patent | gdate = 1964-12-22 | title = 2-Methyl-3-(2'-methyl-3'-chlorphenyl)-quinazolone-(4) | inventor = Klosa, J. (Berlin, Germany) }}</ref> is an analogue of [[methaqualone]] that has similar [[sedative]] and [[hypnotic]] properties.<ref>{{Cite journal 
| last1 = Szirmai | first1 = A. 
| title=(title in German)
| trans_title = Pharmacological and Therapeutic Studies with a New Quinazolone Derivative, Nitromethaqualone 
| language = German 
| journal = Therapeutische Umschau 
| volume = 20 
| pages = 542–546 
| year = 1963 
| pmid = 14101319
}}</ref>
It is significantly more potent (10x) compared to the parent compound; the typical dose is approximately 25&nbsp;mg.<ref name=Boven>{{Cite journal 
| last1 = van Boven | first1 = M. 
| last2 = Daenens   | first2 = P. 
| title = Biotransformation and Excretion of Nitromethaqualone in Rats and Humans 
| journal = Journal of Pharmaceutical Sciences 
| volume = 71 
| issue = 10 
| pages = 1152–1157 
| year = 1982 
| doi = 10.1002/jps.2600711019
| pmid = 7143214
}}</ref> However, the aromatic nitro group is metabolised to the corresponding aniline, which proved to be a [[mutagen]].<ref name=Boven/> As a consequence, nitromethaqualone was not developed further due to toxicity concerns.

== References ==
{{reflist}}

{{Sedatives}}
{{GABAAR PAMs}}

[[Category:Sedatives]]
[[Category:Quinazolinones]]
[[Category:GABAA receptor positive allosteric modulators]]


{{sedative-stub}}